LXRX

Lexicon Pharmaceuticals Stock Analysis

AI Rating

Neutral
  • Quality1/10
  • Growth↑ 8/10
  • Value↓ 1/10
Lexicon Pharmaceuticals sales and earnings growth
LXRX Growth
Good
  • Revenue Y/Y↑ 90.37%
  • EPS Y/Y↑ 86.27%
  • FCF Y/Y↑ 76.97%
Lexicon Pharmaceuticals gross and profit margin trends
LXRX Profitability
Neutral
  • Gross margin ↑ 99.50%
  • EPS margin↓ -37.50%
  • ROIC 5Y↓ -54.82%
Lexicon Pharmaceuticals net debt vs free cash flow
LXRX Risk
Great
  • Debt / Equity↓ 0.2
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -2.2

Lexicon Pharmaceuticals stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks